IT-901

• Description :

  IT-901 is an orally active and potent NF-κB subunit c-Rel inhibitor with an IC50 of 0.1 μM, 3 μM for NF-κB DNA binding and c-Rel DNA binding, respectively. IT-901, a bioactive naphthalenethiobarbiturate derivative, has the potential for human lymphoid tumors and ameliorate graft-versus-host disease (GVHD) [1][2].

• UNSPSC :

  12352005

• Target :

  NF-κB

• Type :

  Reference compound

• Related Pathways :

  NF-κB

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/it-901.html

• Purity :

  99.32

• Solubility :

  DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(/C(C(N1)=O)=C\C2=C3C=CC=CC3=C(OC)C=C2OC)NC1=S

• Molecular Formula :

  C17H14N2O4S

• Molecular Weight :

  342.37

• References & Citations :

  [1]Shono Y, et al. Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in HematologicMalignancies by Blocking NF-κB-Controlled Oxidative Stress Responses. Cancer Res. 2016 Jan 15;76 (2) :377-89.|[2]Vaisitti T, et al. Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cellsby a novel NF-κB inhibitor. Haematologica. 2017 Nov;102 (11) :1878-1889.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  C-Rel; NF-κB

• CAS Number :

  [1584121-99-2]